Histologically or cytologically confirmed prostate adenocarcinoma.
Metastatic prostate cancer.
Organ function meet protocol requirements.
Recovered from all reversible AEs related to previous anticancer treatments.
You may not be if
Previous treatment with the following drugs:
1. AR PROTAC class drugs.
2. Other systemic anticancer therapy within 3 weeks or 5 half-lives prior to the first administration of the study treatment.
3. Taditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first administration of the study treatment.
4. Drugs that may cause drug-drug interactions (DDI) with the study treatment.
5. Drugs known to prolong the QT interval or potentially cause torsades de pointes ventricular tachycardia
Presence of central nervous system metastases, leptomeningeal metastasis, or spinal cord compression.
Radiation therapy involving more than 25% of bone marrow within 4 weeks prior to the first administration of the investigational medicinal product; local radiation therapy within 2 weeks prior to the first administration of the investigational medicinal product.
Treatment with other investigational drugs or major surgery within 4 weeks.
Inability to swallow, chronic diarrhea, intestinal obstruction, or other factors affecting drug intake and absorption.
With severe cardiovascular or cerebrovascular diseases or related history.
Active, uncontrolled infections.
History of other significant malignancies within 5 years.
Moderate to severe pulmonary disease significantly affecting lung function.
According to the investigator's judgment, there are comorbidities that seriously endanger subject safety or affect the subject's ability to complete the study.
Allergy to any of the investigational medicinal products or their components.
Clareo Health | Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer
